The BASDAI Calculator scores ankylosing spondylitis disease activity from six patient-reported domains: fatigue, spinal pain, peripheral joint pain, enthesitis, and morning stiffness severity and duration. Score ≥4 is the international threshold for biologic disease-modifying therapy consideration.
Enter values to see results
—
—
—
Enter values to see results
—
—
—
Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) are inflammatory conditions whose severity fluctuates in ways that objective markers like CRP and MRI sometimes fail to capture. The BASDAI — a patient-reported outcome measure developed in Bath in 1994 — translates the subjective experience of disease activity into a 0–10 numerical score that has become the cornerstone of treatment escalation decisions in axial spondyloarthritis management worldwide. The calculator for BASDAI applies the correct weighted formula to compute the composite score from six NRS responses.
Each question is answered on a 0–10 numerical rating scale (NRS) where 0 = none and 10 = very severe. The composite BASDAI is not a simple average — questions 5 and 6 (morning stiffness severity and duration) are averaged first, then this average is added to questions 1–4, and the total is divided by 5:
BASDAI = (Q1 + Q2 + Q3 + Q4 + [(Q5 + Q6)/2]) / 5
Questions:
Use this online calculator to compute the composite BASDAI from any six responses. The Wells score calculator demonstrates the complementary use of clinical scoring in related rheumatic conditions.
The BASDAI score drives treatment escalation decisions according to major international guidelines (ASAS/EULAR, ACR/SAA):
The newer Ankylosing Spondylitis Disease Activity Score (ASDAS), which incorporates CRP or ESR, is increasingly used alongside BASDAI in clinical practice and trials for its superior discriminatory performance — a BASDAI-only threshold can be elevated by non-inflammatory symptoms (fibromyalgia comorbidity, depression, poor sleep) that do not reflect true axial inflammatory burden.
Axial spondyloarthritis presents a measurement challenge: the primary pathology (sacroiliitis, spinal enthesitis) is often not visible on conventional X-rays until years of disease have passed, and active spinal inflammation on MRI correlates imperfectly with clinical symptoms. CRP is normal in 30–40% of active AS patients. Patient-reported outcomes like BASDAI fill this measurement gap by capturing the subjective experience of disease burden that matters most to patients and their ability to maintain employment, physical function, and quality of life. The BASDAI's pain and stiffness components correlate significantly with sleep disturbance, disability (measured by BASFI), and work absenteeism — making it not just a treatment threshold tool but a comprehensive disease impact measure. The Ottawa ankle rules calculator and orthopedics and rheumatology calculators provide complementary musculoskeletal assessment tools.
Both BASDAI and ASDAS (Ankylosing Spondylitis Disease Activity Score) are validated for axial SpA disease activity assessment but have different properties. BASDAI is purely patient-reported, feasible in any setting, and the traditional biologic prescription threshold tool. ASDAS incorporates CRP (or alternatively ESR), making it more sensitive to objective inflammation changes and less prone to inflation by non-specific symptoms; ASDAS inactive disease (<1.3) is now the EULAR/ASAS treatment target in axial SpA. For clinical trials, ASDAS is increasingly preferred as a primary endpoint; for routine clinical practice, both measures provide complementary information — BASDAI capturing patient experience and ASDAS capturing objective inflammation.
BASDAI is calculated from six 0-10 VAS questions:
BASDAI = (Q1 + Q2 + Q3 + Q4 + mean(Q5,Q6)) / 5
Disease Activity: 1=Inactive/Low (<4), 2=Active (>=4). Biologic Threshold: 1=Yes (>=4), 0=No (<4).
A BASDAI score below 4 indicates inactive or low disease activity — current treatment is generally adequate. A BASDAI of 4 or higher indicates active disease and may qualify the patient for biologic therapy if NSAIDs have failed. The closer the score is to 10, the more severe the disease burden. Serial measurements should show improvement after treatment changes. A decrease of 2 or more points or 50% improvement is considered clinically meaningful.
Inputs
Results
Significant fatigue, spinal pain, and morning stiffness. BASDAI 5.7 indicates active disease meeting the biologic therapy threshold.
Inputs
Results
Minimal symptoms across all domains. BASDAI 1.1, low disease activity. Current treatment is effective.
BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) is a validated patient-reported questionnaire consisting of six questions that measures disease activity in ankylosing spondylitis on a 0-10 scale.
A BASDAI of 4 or higher is the internationally accepted threshold for active disease. It is a key criterion for eligibility for biologic therapies like TNF inhibitors and IL-17 inhibitors.
BASDAI should be measured at every rheumatology visit, typically every 3-6 months during active treatment. For biologic therapy eligibility, two measurements at least 4 weeks apart showing scores of 4 or above are required.
Enthesitis is inflammation at the sites where tendons and ligaments attach to bone. Common sites in AS include the Achilles tendon, plantar fascia, and iliac crest. It is a hallmark feature of spondyloarthropathies.
BASDAI is entirely patient-reported. ASDAS (AS Disease Activity Score) combines patient-reported outcomes with CRP, providing a more objective measure. ASDAS is increasingly preferred for treatment decisions.
Yes, BASDAI is used for the entire spectrum of axial spondyloarthropathy, including both ankylosing spondylitis (with X-ray changes) and non-radiographic axial SpA (without X-ray changes).
An improvement of 50% or an absolute change of 2 or more points from baseline is generally considered clinically meaningful. This is used to assess treatment response in clinical trials and practice.
Morning stiffness is a cardinal symptom of AS. Assessing both severity and duration captures the full impact. A patient may have severe but brief stiffness, or mild but prolonged stiffness — both patterns are relevant.
BASDAI correlates modestly with MRI inflammation but poorly with radiographic structural damage. High BASDAI over time may predict future structural progression, but the relationship is not straightforward.
NSAIDs are first-line and can significantly reduce BASDAI. Biologic therapies (TNF inhibitors like adalimumab, etanercept; IL-17 inhibitors like secukinumab) typically reduce BASDAI by 2-4 points in responders.
How helpful was this calculator?
Be the first to rate!
